SHA
LGND icon

Smith Hayes Advisers’s Ligand Pharmaceuticals LGND Stock Holding History

Smith Hayes Advisers’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,206
Closed -$202K – 306
2015
Q2 		$202K Buy
+3,206
New +$175K 0.04% 307

Other funds holding LGND

RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DMK
David M. Knott $275M AUM 59.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Smith Hayes Advisers's LGND Position: Q3 2015 in Review

Smith Hayes Advisers sold out of Ligand Pharmaceuticals (LGND) in Q3 2015, closing a stake of 3,206 shares — an estimated $202K sold.

Smith Hayes Advisers first reported a position in LGND in Q2 2015 and held it in 1 quarter. The position peaked at $202K in Q2 2015. 203 funds tracked by Wall St. Rank hold LGND as of Q3 2015.

  • Smith Hayes Advisers reported no remaining Ligand Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Smith Hayes Advisers sold 3,206 Ligand Pharmaceuticals shares in Q3 2015, an estimated $202K.
  • Smith Hayes Advisers first reported a position in Ligand Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Smith Hayes Advisers's Ligand Pharmaceuticals position peaked at $202K in Q2 2015.
  • 203 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2015.

Based on Smith Hayes Advisers's 13F filing for Q3 2015, filed 13 Nov 2015.